AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
- Booth number: 2
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases. Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, hepatitis B and hepatitis C, HIV/AIDS and rheumatoid arthritis.
- Booth number: 13
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit the company website.
For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, MSD continues be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.
- Booth number: 14
Pfizer Oncology is committed to pursuing innovative treatments that are helping to redefine life with cancer. As an oncology leader with one of the most robust oncology pipelines in the industry, we are focused on translating scientific breakthroughs into clinical application. Additionally, we are dedicated to working collaboratively with the community to make a positive impact on people’s lives.
- Booth number: 3
At Boehringer Ingelheim we are taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer.
- Booth Number: 10a
Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1 antibody. The alliance is focused on developing high-priority international clinical programs to investigate avelumab, as a monotherapy, as well as combination regimens, and is striving to find new ways to treat cancer.
- Booth Number: 11
At Novartis, our mission is to discover new ways to improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
- Booth Number: 20
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Lung cancer is a major area of focus and investment for Roche, with the objective to develop new approaches, medicines and tests that can help people with this deadly disease. With the combined strength in pharmaceuticals and diagnostics, Roche is dedicated to further drive personalised healthcare. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and lately employed more than 94,000 people worldwide.
- Booth Number: 15
Takeda Pharmaceuticals International AG
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.
Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines.
Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. For more information, visit the News section on company website.
- Booth Number: 10b
Bavarian Nordic is committed to building a pipeline of immunotherapy candidates targeting cancers with high unmet medical needs. In collaboration with the National Cancer Institute, BN has developed a portfolio designed to alter the disease course by eliciting robust and broad anti-cancer immune responses while maintaining favorable risk-benefit profiles. Through multiple industry collaborations, BN seeks potential synergies of combining our immunotherapies with other immune-modulating agents.
- Booth Number: 19a
Beacon Medicare Limited
BEACON Medicare Limited is the sister concern of BEACON Group and Global Marketing Partner of BEACON Oncology Limited. BEACON is the Number 1 Oncology company and one of the leading pharma companies of Bangladesh. The company has started its business operation in 2006 with a vision of caring global patient. BEACON manufactures 85 life saving anti-cancer products. Besides the conventional chemotherapy products, BEACON manufactures MABs, Targeted therapies, Nano and Lyposomal preparations. After meeting the local demand, BEACON exports its medicines globally. Patients of 115 countries including USA, Europe, Australia are using BEACON’s medicines.
- Booth Number: 21
Biocartis aims to provide direct access to personalized medicine for patients worldwide by developing fully integrated, broadly applicable molecular diagnostics. Biocartis’ MDx Idylla™ platform is a fully automated sample-to-result, real-time Polymerase Chain Reaction system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting.
- Booth Number: 16
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of novel medicines to meet serious unmet medical needs in cancer and other diseases. Incyte is committed to the rigorous pursuit of R&D excellence to improve the lives of patients, make a difference in health care, and build sustainable value.
The Company strives to discover and develop first-in-class and best-in-class medicines—advancing a diverse portfolio comprised of 18 development candidates against 14 different molecular targets.
Headquartered in Wilmington, Delaware, Incyte has offices in Switzerland, nine other European countries and Japan. For more information, visit the company website and follow @Incyte.
- Booth Number: 17
Sysmex Europe GmbH
Sysmex is a global leader in diagnostic solutions with specialist technologies that help improve cancer management. Sysmex Inostics, a Sysmex Corporation subsidiary, is a pioneer in blood-based cell-free tumour DNA testing, including OncoBEAM Digital PCR. It provides new assays for clinical applications in oncology and offers global services for pharma – from discovery to companion diagnostics.
- Booth Number: 19b
Amoy Diagnostics Co., Ltd.
Amoy Diagnostics Co., Ltd. (AmoyDx) is an R&D based provider of state-of-the-art diagnostic products and services in the area of human oncology personalized healthcare. We have a rich portfolio of tests that focuses on detecting mutations and measuring gene expression in various sample types including FFPE cancer tissue, body fluids, and whole blood.
- Booth Number: 22
Epigenomics in concert with the European Union’s Horizon 2020 research and innovation program has developed Epi proLung®. Epi proLung is a combination of methylation biomarkers SHOX2 and PTGER4. The product has received CE-IVD mark in Europe. Epi proLung is intended to clarify indeterminate findings and aid in early identification of illness, improved outcomes, and reduce unnecessary procedures.
- Booth Number: 24
Roche Diagnostics Information Solutions
Diagnostics Information Solutions (DIS) is chartered with making Roche Diagnostics the partner of choice to healthcare stakeholders by providing data-driven information solutions for better patient care and smarter, more efficient R&D. Access to data combined with Roche’s background in diagnostics, medicine and biology enables insights that will usher in a new era of patient-centric healthcare through better-informed decision support.
- Booth Number: 23
Wisepress.com, Europe’s leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.
- Booth Number: 25